Filing summary
Entity note: The supplied filing is Diffusion Pharmaceuticals Inc.’s Form 10-Q, not a filing for Cervomed Inc. It covers the unaudited quarter ended March 31, 2022 and was signed May 12, 2022.
Business context and reporting period
Diffusion is a clinical-stage biopharmaceutical company developing trans sodium crocetinate (TSC), intended to improve oxygen delivery to hypoxic tissues. It has no product-sales revenue and is focused on clinical development, particularly a planned program in hypoxic solid tumors.
Financial results and liquidity
| Metric | Q1 2022 | Q1 2021 / comparison |
|---|---|---|
| Revenue | No product-sales revenue | No product-sales revenue |
| Research and development expense | $2.43 million | $2.92 million; down $0.49 million |
| General and administrative expense | $2.13 million | $1.74 million; up $0.39 million |
| Operating loss | $4.55 million | $4.68 million |
| Net loss | $4.53 million | $4.64 million |
| Net loss per share | $2.22 | $2.81 |
| Operating cash used | $4.73 million | $5.18 million |
At March 31, cash and cash equivalents were $9.87 million and marketable securities were $22.68 million, totaling $32.55 million. Working capital was $30.6 million; current liabilities were $2.96 million and total stockholders’ equity was $30.62 million. The filing reports no credit facilities or committed capital and no material off-balance-sheet arrangements. Gross margins are not applicable because the company had no product revenue.
Cash and cash equivalents declined from $37.31 million at year-end 2021, partly because $22.72 million was used to purchase marketable securities. There was $5,000 of financing cash inflow in Q1 2022, compared with $33.30 million in Q1 2021 from common-stock sales and warrant exercises.
Changes versus prior comparable period
- Net loss improved by approximately $117,000. R&D expense fell, largely due to clinical-trial and drug-manufacturing timing, while G&A increased with higher personnel, stock compensation, and professional fees.
- Q1 2022 included $22.68 million of marketable securities; the company held none at December 31, 2021. The securities’ $49,658 unrealized loss was attributed primarily to interest-rate changes; no impairment or realized gains or losses were recorded.
- Cash used in operations decreased by approximately $447,000 year over year. Financing inflows were substantially lower than in Q1 2021.
Outlook, risks and notable items
- Management estimated that March 31 cash, cash equivalents, and marketable securities would fund operating expenses and capital needs through 2023. It expects continued losses and substantial spending, and says additional financing will be needed to complete TSC development; funding is not assured.
- The Altitude Trial completed dosing on April 11, 2022; topline data were expected in June 2022. The ILD-DLCO Trial was ongoing, with dosing completion expected in the second half of 2022 and results expected within two months after completion.
- The planned Phase 2 hypoxic-tumor trial was expected to begin in the second half of 2022, subject to FDA feedback and availability of clinical drug supply. These are forward-looking expectations, not guarantees.
- On April 18, 2022, after quarter-end, the company effected a 1-for-50 reverse stock split and converted 10,000 Series C preferred shares issued to its CEO and general counsel for $5,000 into 200 common shares. On May 3, Nasdaq confirmed the company had regained compliance with its minimum bid-price requirement.
- A former executive’s legal action remained pending; trial was set for May 24, 2023, with mediation planned. The company disputes the claims but said it could not estimate a potential loss or its effect.
- Management cited risks including clinical and regulatory uncertainty, manufacturing and enrollment, reliance on additional financing, and possible dilution or reduced development rights under future financing or collaboration arrangements. The filing reported disclosure controls were effective and no material change in internal control during the quarter.
Important facts for investors to verify
- Whether the company secured funding beyond its estimated 2023 runway, and the resulting dilution or other financing terms.
- Actual timing, enrollment, drug supply, and results for the Altitude, ILD-DLCO, and planned hypoxic-tumor trials, including any FDA feedback.
- Whether clinical evidence supports TSC’s effectiveness and safety; the filing notes prior small Phase 2 results were not statistically significant.
- Developments and any potential financial exposure in the pending legal matter.
- The impact of the reverse split and preferred-stock conversion on share counts; the filing applies the split retroactively to share and per-share figures.